Abstract
We studied the impact of zidovudine (AZT) in Cas-Br-M murine leukemia virus-infected NFS-N mice after administration by once-daily bolus or continuous infusion. While higher peak concentrations of AZT were achieved by once-daily dosing, continuous AZT infusion at 25 micrograms/h maintained levels > 1 microM in plasma and > 0.2 microM in the brain. Continuous infusion provided significantly better viral inhibition, even though total doses were only one-third that of the once-daily therapy group.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
AIDS Dementia Complex / drug therapy*
-
AIDS Dementia Complex / microbiology
-
Animals
-
Brain / metabolism
-
Chromatography, High Pressure Liquid
-
Electrophoresis, Polyacrylamide Gel
-
Female
-
Half-Life
-
Immunoblotting
-
Mice
-
Mice, Inbred Strains
-
Pregnancy
-
Retroviridae Infections / drug therapy*
-
Retroviridae Infections / microbiology
-
Retroviridae*
-
Spleen / microbiology
-
Zidovudine / administration & dosage*
-
Zidovudine / pharmacokinetics
-
Zidovudine / therapeutic use*